Scientific Advisory Board

Dr. Flaherty is a Professor of Medicine at Harvard Medical School and Director of Clinical Research at the Massachusetts General Hospital Cancer Center. He co-founded and served on the board of directors of Loxo Oncology until its acquisition by Eli Lilly and Company, and he has served on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles, abstracts and reviews in peer-reviewed literature, including three first-author and three senior author New England Journal of Medicine papers. He serves as Editor-in-Chief for Clinical Cancer Research and on the Board of Directors of the American Association for Cancer Research. Dr. Flaherty holds a Bachelor of Science degree from Yale University and an M.D. from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.

Dr. Baum is Chief Executive Officer at Terremoto and has served on the board of directors since July 2023. Prior to becoming the CEO at Terremoto, Dr. Baum was the Founder, President and Chief Executive Officer of Mirati Therapeutics, where he also served as a board member since 2012 through its recent acquisition by Bristol Meyers Squibb in 2024. He was Founder, President and Head of Research and Development at Mirati from 2021 to 2023 and was Founder, President Chief Executive Officer from November 2012 to 2021.

Dr. Baum received his M.D. and Ph.D. degrees from Washington University School of Medicine and completed his postgraduate training at Stanford University. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications.